

#### inclusion Criteria

Neonates with an unexplained, nonhemolyzed NH<sub>3</sub> level >64uM (upper limit of normal at NCH lab)

#### Exclusion criteria

•

•

•

•

- Premature infants <34 weeks GA
- Onset in first day of life
- Liver failure

#### ¶ **Sampling Considerations**

- NH<sub>3</sub> should be collected as • a free flowing sample (not capillary), transferred to the lab on ice and run STAT.
- Thresholds in this pathway presume non-hemolyzed samples.
- Whether a hemolyzed NH3 • level is sufficiently elevated to warrant attention even while it is being repeated is outside of the scope of this pathway.

#### \* Moderate or Severe **Encephalopathy:**

- Attributable to . hyperammonemia
- By Sarnat exam (including seizures)

#### V Rapidly Rising NH<sub>3</sub>:

• Rising by more than 300uM in a few hours despite adequate therapy (per clinical discretion)

### Abbreviations



GIR: Glucose Infusion Rate

# Neonatal Hyperammonemia **Clinical Pathway**

### **Center for Clinical Excellence**





- Airway: Consider cuffed Endotracheal Tube (if requiring intubation)
- Breathing: Control respiratory alkalosis (if intubated)
- Circulation: patients with severe hyperammonemia are at risk for circulatory collapse. Steroids are relatively contraindicated.
- Make neonate NPO. Start IV fluids with GIR: 10 mg/kg/min (for • transport or if unstable)
- Consult Genetics early in the transfer process •



CPP-NICU Hyperammonemia Clinical Pathway Published: 8/18/2023 Revised: 8/18/2023

**Off Pathway** 

collaboration with

Genetics

# Low Risk Hyperammonemia Care Management



# High Risk Hyperammonemia Care Management



CPP-NICU Hyperammonemia Clinical Pathway Published: 8/18/2023 Revised: 8/18/2023



# CRRT For Severe Hyperammonemia





# **Diagnosis & Definition**

- Treatment of severe hyperammonemia (> 400uM or moderate/severe encephalopathy due to hyperammonemia) is a <u>medical emergency</u>. Patients with hyperammonemia are at high risk for irreversible severe neurologic impairment. This risk increases with the duration and level of hyperammonemia, so prompt reduction in NH<sub>3</sub> is critical.
- 2. Treatment of severe hyperammonemia will be a collaborative effort between Genetics, Nephrology, Critical Care, and Interventional Radiology (catheter placement).
- 3. Treatment includes medical management in all patients, and high-dose CRRT in a select group of patients. Decisions regarding CRRT will take into account the underlying diagnosis, patient stability, trend in NH<sub>3</sub> levels, and response to nutritional and nitrogen-scavenger therapy.
- 4. In patients with severe hyperammonemia with potential need for CRRT will be transferred urgently to H2B PICU for care coordination.
- 5. Patients identified to have severe hyperammonemia (NH<sub>3</sub> > 400uM) at an outside institution will be admitted directly to H2B PICU.
- 6. The NICU team will provide consultative care for neonates during H2B PICU admission. As soon as stable off CRRT, neonates will be transferred to the NICU for continued care.

<u>Risk Stratification</u> <u>Algorithm</u>

<u>Low Risk</u> <u>Hyperammonemia</u> <u>High Risk</u> <u>Hyperammonemia</u>

# Hyperammonemia Huddle

- 1. Primary team places STAT Nephrology consult and notifies Nephrology attending of Hyperammonemia huddle
- 2. Primary team places STAT Genetics consult and notifies Genetics attending of Hyperammonemia huddle
- Primary team coordinates multidisciplinary care huddle that includes the Primary team, Nephrology and Genetics teams (attending physicians to be involved with respective team members)
- 4. Depending on situation, this can be achieved through In-person or virtual group meeting, or 3-way phone/vocera communication
- 5. Primary team should proceed with process for PICU transfer during interim (see pathway specifics).

# **Medications**

## Sodium Benzoate-Sodium Phenylacetate 10% & Arginine 10% (Ammonul & Arginine)

- Utilize Ammonul Infusion Load + Maintenance Orderset in EPIC for dosing
- Loading dose given over 90-120 minutes
- Maintenance dose given over 24 hours
- Infusion via central line is preferred. May be given peripherally if emergently needed.
- Repeated boluses of Ammonul & Arginine are to be avoided
- Patients should be monitored for electrolyte and acid-base disturbance while on Ammonul & Arginine
- Administration of analogous oral drugs, such as sodium phenylbutyrate, should be stopped prior to Ammonul infusion (patients may arrive receiving such medicines on transport)
- Continuation of Ammonul & Arginine during CRRT is a joint decision between Genetics and Nephrology
- Medical necessity of maintenance doses of Ammonul & Arginine should be discussed with Genetics daily

### Levocarnitine

- Loading: 50 mg/kg IV or enteral
- Maintenance: 100mg/kg/day IV or enteral, continuous or divided q6-8h

### Biotin

- 10mg flat dose, enteral
- Discuss with genetics prior to ordering
- Genetics may recommend a one time dose or daily dosing based on the clinical scenario

### Hydroxocobalamin

- 1mg flat dose, IM
- Discuss with genetics prior to ordering
- Genetics may recommend a one-time dose or daily dosing based on the clinical scenario

## Carglumic acid (Carbaglu)

- 100-250mg/kg/day enteral, divided q6h
- Round each dose to the nearest 50mg
- Discuss with genetics prior to ordering

<u>Risk Stratification</u> <u>Algorithm</u>

<u>Low Risk</u> <u>Hyperammonemia</u> <u>High Risk</u> <u>Hyperammonemia</u>

# **High Dose CRRT**

- 1. PrisMax machine with HF20 (<12 kg)
- 2. Blood flow of 30-50 ml/min
- 3. Dialysate and replacement fluid at total clearance of 8000 ml/hr/1.73m2
  - a. Dialysate rate at 7000 ml/hr/1.73m2
  - b. Replacement fluid rate at 1000 mL/hr/1.73m2
- 4. Citrate anticoagulation per CRRT protocol
  - a. Reduce citrate rate by 50% due to immaturity of neonatal liver function.
  - b. Administer standard calcium rate.
- 5. Duration of high dose CRRT will be determined according to serum  $NH_3$  levels and clinical status
- 6. Lab monitoring:
  - a. Serum NH<sub>3</sub> hourly
  - b. Serum osmolality, renal function panel and magnesium every 6 hours
- When serum NH<sub>3</sub> falls < 200uM x 2 consecutive measurements, plan will be to provide step-down CRRT to prevent NH<sub>3</sub> rebound.
  - In select cases, Genetics and Nephrology may consider stopping CRRT and providing only medical management. This should only be considered in patients felt to have low risk of NH<sub>3</sub> rebound.
- 8. If CRRT is required for a patient on ECMO, the PrisMax machine will be placed in line with ECMO circuit with clearance rates as outlined in previous sections
  - CRRT must still take place in PICU (NICU does not have CRRT nursing staffing)

<u>Risk Stratification</u> <u>Algorithm</u>

**CRRT Algorithm** 

# **Step-Down CRRT**

- 1. When NH<sub>3</sub> is <200uM x 2 measurements, nephrology will modify CRRT orders to reduce clearance to 2000 ml/1.73m2/hr (50% dialysate, 50% replacement fluid)
- 2. Lab monitoring:
  - a. Serum  $NH_3$  every 4 hours
  - b. Serum osmolality, renal function panel and magnesium every 8 hours
- 3. Step-down CRRT should be continued until  $NH_3$  is <100uM x 1 measurement and Genetics team feels patient is likely to be stable on medical management only.
- 4. At completion of CRRT, lines should be clamped if the circuit was primed with blood (i.e., do NOT return the blood in the system to the patient to avoid acutely increasing the child's blood volume and providing a protein load from blood cells).
- 5. Continue monitoring NH<sub>3</sub> levels in PICU q 4 hours for 24 hours after CRRT discontinuation to assess for rebound.

Risk Stratification Algorithm

**CRRT Algorithm** 

# References

- 1. Auron A, Brophy PD. Hyperammonemia in review: Pathophysiology, diagnosis, and treatment. *Pediatric Nephrology*. 2011;27(2):207-222. doi:10.1007/s00467-011-1838-5
- Spinale JM, Laskin BL, Sondheimer N, Swartz SJ, Goldstein SL. High-dose continuous renal replacement therapy for neonatal hyperammonemia. *Pediatric Nephrology*. 2013;28(6):983-986. doi:10.1007/s00467-013-2441-8
- Raina R, Bedoyan JK, Lichter-Konecki U, et al. Consensus guidelines for management of hyperammonaemia in paediatric patients receiving continuous kidney replacement therapy. *Nature Reviews Nephrology*. 2020;16(8):471-482. doi:10.1038/s41581-020-0267-8
- Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. *Journal of Inherited Metabolic Disease*. 2019;42(6):1192-1230. doi:10.1002/jimd.12100

# **Quality Measures**

## Goal:

 Initiate CRRT within 4 hours of identification of severe hyperammonemia (NH<sub>3</sub> >400uM OR rapidly rising NH<sub>3</sub> OR moderate/severe encephalopathy).

## Outcome Measure:

Time to initiate CRRT

## Process Measures:

- Time for transfer to the PICU (Goal is to transfer within 1 hour of identification of severe hyperammonemia)
- Time for dialysis catheter placement (Goal is catheter placement within 2 hours of identification of severe hyperammonemia)
- Time from order to administration for Ammonul (Goal is to give the loading Ammonul dose within 90 minutes of order placement)

<u>Risk Stratification</u> <u>Algorithm</u>

# **Team & Process**

Pathway Development Team		Clinical Pathways Program: Medical Director – Neonatology:		
Leader(s):		modical Director Moonatology.		
Genetics & Genomic Medicine:		Roopali Bapat, MD, MSHQS		
Nephrology:	Bimal Chaudhari, MD, MPH	Medical Director – Quality:		
	Beth Vogt, MD	Rvan Bode, MD, MBOF		
Neonatology:	-			
	Roopali Bapat, MD, MSHQS	Medical Director – Clinical Informatics & Emergency Med	ergency Medicine:	
Members:		Laura Rust, MD, MPH		
Neonatology:		Business & Development Manager:		
	Molly Ball, MD Jill Jones, MS, APRN, NNP-BC	Rekha Voruganti, MBOE, LSSBE	3	
Shama Patel, MD, MPH		Program Coordinators:		
Genetics & Genomic Medicine:		Table Brown MBA		
Critical Care		Tanje Brown, MBA		
	Samantha Gee, MD, FAAP Jill Fitch, MD, FAAP	Joaquin Serantes, BA		
Clinical Pharmacy:	Elera Hilman DharmD, PCDS	Clinical Pathway Approved		
	Jacqueline Magers, PharmD	Medical Director – Associate Chief Quality Officer Cente	r for	
Nephrology:		Clinical Excellence:		
1 05	Stephanie Peters, APN	Ryan Bode, MD, MBOE		
		Advisory Committee Date: August 2023		
		Origination Date: August 2023		
		Next Revision Date: August 2026		

### **Clinical Pathway Development**

This clinical pathway was developed using the process described in the NCH Clinical Pathway Development Manual Version 6, 2022. Clinical Pathways at Nationwide Children's Hospital (NCH) are standards which provide general guidance to clinicians. Patient choice, clinician judgment, and other relevant factors in diagnosing and treating patients remain central to the selection of diagnostic tests and therapy. The ordering provider assumes all risks associates with care decisions. NCH assumes no responsibility for any adverse consequences, errors, or omissions that may arise from the use or reliance on these guidelines. NCH's clinical pathways are reviewed periodically for consistency with new evidence; however, new developments may not be represented, and NCH makes no guarantees, representations, or warranties with respect to the information provided in this clinical pathway.

Copyright © 2023. Nationwide Children's Hospital. All rights reserved. No part of this document may be reproduced, displayed, modified, or distributed in any form without the express written permission of Nationwide Children's Hospital.

### For more information about our pathways and program please contact: ClinicalPathways@NationwideChildrens.org

### \*NEUROLOGIC EXAM (Modified Sarnat) CERTIFICATION FORM

#### Seizures?

Ν

Y

See definitions for Neurologic Examination on page 2

CATEGORY N=6	SIGNS OF HIE IN EACH CATEGORY			
	NORMAL/MILD HIE	MODERATE HIE	SEVERE HIE	
1. LEVEL OF CONSCIOUSNESS	1	2 = Lethargic	3 = Stupor/coma	
2. SPONTANEOUS ACTIVITY	1	2 = Decreased activity	3 = No activity	
3. POSTURE	1	2 = Distal flexion, complete extension	3 = Decerebrate	
4. TONE	1	2a = Hypotonia (focal or general) 2b = Hypertonia	3a = Flaccid 3b = Rigid	
5. PRIMITIVE REFLEXES			30 - Rigiu	
Suck	1	2 = Weak or has bite	3 = Absent	
Moro	1	2 = Incomplete	3 = Absent	
6. AUTONOMIC SYSTEM				
Pupils	1	2 = Constricted	3 = Deviation/dilated/non-reactive	
Heart rate	1	2 = Bradycardia	3 = Variable HR	
Respiration	1	2 = Periodic breathing	3 = Apnea or requires ventilator 3a=on vent with spontaneous breaths 3b=on vent without spontaneous breaths	

### **CATEGORY**

٠

### SIGNS OF HIE IN CATEGORY

1.	Level of Consciousness			
2.	Spontaneous Activity			
3.	Posture			
4.	Tone			
-			(Note <u>a</u> or <u>b</u> )	
5.	Primitive Reflexes (Suck or Moro, code highest level)			
6.	<ol><li>Autonomic System (Pupils, Heart Rate or Respirations, code highest level)</li></ol>			
	lf vent, code 3a or 3b			
ls the	infant sedated/paralyzed?	Y	N	

### Total # Categories should be NO MORE THAN 6 (Count Only the Highest Level in each sign)

The level of encephalopathy will be assigned based on which level of signs (moderate or severe) | predominates among the 6 categories. If moderate and severe signs are equally distributed, the designation is then based on the highest level in Category #1: The level of consciousness.

•	Signs of moderate or severe HIE in at least 3 of the	e 6 categories above?	Y N (circle one)
	If yes, what is the Level of HIE?	MODERATE or	SEVERE (circle one)

Name of examiner\_\_\_\_\_Exam date & time: \_\_\_/\_\_/\_\_\_ at \_\_\_:\_\_\_\_

#### DEFINITIONS FOR NEUROLOGIC EXAMINATION

 Did the infant have documented seizures? Record 'Y" if seizures have been diagnosed or if the infant's chart or verbal summary included the diagnosis of seizures. Seizures can be subtle such as ocular deviation, sucking and lip smacking movements, swimming or "rowing" or based on tone in these areas. If responses differ in multiple areas, base code on the lower extremity.

5. Primitive reflexes: (remember: count only one sign in this category—the highest level of HIE)

Suck: Code "1" if infant vigorously sucks your finger inserted in mouth or around the tube if intubated. Code "2" if suck is weak or infant has bite. Code "3" is suck is absent.
Moro: Code "1" if Moro is normal – extension of limbs opening of hands, extension with abduction of UE (flexion of the UE has been removed) Code "2" if incomplete. Code "3" if absent.

"bicycling" movements of limbs. They can be tonic/clonic, localized, multifocal or generalized.

 Does the infant have signs of moderate or severe encephalopathy in > 3 categories (3 of the 6 categories) on the neurologic examination?

1. Level of consciousness: Code "1" if infant arouses to wakefulness, responds appropriately and promptly to external stimuli, or appears hyperalert or inconsolable/irritable, Code "2" if lethargic delayed but complete response to external stimuli (start with mild stimuli first then proceed to more noxious stimuli. Code "3" if stupor/coma (infant is not arousable and is nonresponsive to external stimuli. may have a delayed but incomplete response to stimuli).

2. Spontaneous activity: Code "1" if infant is active. Code "2" if activity is decreased. Code "3" if no activity.

Spontaneous Activity Notes: if infant is, sedated clinical judgment has to be used to decide whether the examination is reliable. Paralysis will preclude a meaningful exam.

3. Posture: Code "1" if infant is moving around and does not maintain only one posture, should have flexion or lower extremity at hip and/or knees Code "2" if strong distal flexion, complete extension, or "frog-legged" position. Code "3" if decerebrate with or without stimulation.

Posture Notes: If posture is abnormal, but does not fit 2 or 3, code as 2.

4. Tone: Code "1" if tone is normal (resistance to passive motion). Code "2a" if hypotonic or floppy, either focal or generalized. Code "2b" if hypertonic or increased tone or tension of extremities or trunk upon passive movement. Code "3a" if infant lies like a rag doll with no tone at all (flaccid). Code "3b" if the infant is rigid with extreme stiffness or inflexibility of extremities or trunk upon passive movement.

Tone Notes: Evaluate extremities, trunk and neck tone and make clinical judgment of tone Moro Notes: If neonate has fracture of clavicle or brachial plexus injury, evaluate other extremity. Moro has to be done by gently raising and lowering the head when infant is intubated

#### 6. Autonomic system: (remember: count only one sign in this category—the highest level of HIE)

Pupils: Code "1" if normal in size and reactive to light. Code "2" if constricted and reacting to light. Code "3" if skew deviation of eyes, pupils are dilated or non-reactive to light.

Pupil Notes: If pupils asymmetric, assign 3. Pupils are difficult to assess in the newborn infant with edema of eyelids---you will need to gently separate the eyelids while a second person shines light.

□ Heart rate: Code "1" if normal heart rate > 100/minute consistently or tachycardia. Code "2" if bradycardia (< 100/minute) with only occasional increases to > 120/minute. Code "3" if heart rate is not constant and varies widely between <100 and > 120

Heart Rate Notes: Heart rate should be evaluated based on documented rate over the previous min/hrs. Do not code heart rate if cooling has been initiated.

 Respiration: Code "1" if breathing spontaneously. Code "2" if periodic breathing associated with desaturation events (< 80%).</li>
Code "3" if apnea or requiring ventilator support.